Evidence map›Paper›PMID 38046039›Full record

ArticleClinical kidney journal2023

Standardized 4-point scoring scale of [

Selina Demuynck, Pierre Lovinfosse, Laurence Seidel, Sander Jentjens, Djalila Mekahli, François Jouret, Bert Bammens, Karolien Goffin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Performance of [Diagnostics (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Selina DemuynckDepartment of Nephrology, Dialysis and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium.
Pierre LovinfosseDivision of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, University of Liège Hospital, Liège, Belgium.
Laurence SeidelBiostatistics and Research Method Center (B-STAT), University of Liège Hospital (ULiège CHU), Liège, Belgium.
Sander JentjensNuclear Medicine, UZ Leuven, Leuven, Belgium; Nuclear Medicine & Molecular Imaging, KU Leuven, Leuven, Belgium.
Djalila MekahliPKD Research Group, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
François JouretDivision of Nephrology, Department of Internal Medicine, University of Liège Academic Hospital (ULiège CHU), Liège, Belgium.ORCID https://orcid.org/0000-0003-2547-6593
Bert BammensDepartment of Nephrology, Dialysis and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium.
Karolien GoffinNuclear Medicine, UZ Leuven, Leuven, Belgium; Nuclear Medicine & Molecular Imaging, KU Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Autosomal dominant polycystic kidney disease (ADPKD) is prone to multiple complications, including cyst infection (CyI). 2-Deoxy-2-[ Methods: All ADPKD patients hospitalized between January 2009 and November 2019 who underwent an [ Results: Fifty-one [ Conclusions: Our independent validation cohort confirms the use of a semi-quantitative 4-point scoring system of [

Indexed as

ADPKD, cyst infection, [18F]-FDG PET/CTstandardized scoring system

Identifiers

PMID38046039
PMCPMC10689132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.